Loading...
Loading...
Amneal Pharmaceuticals announced today that it has
entered into agreements with subsidiaries of Actavis, Inc.
ACT to
purchase four generic products for cash consideration. One product is
currently marketed in the U.S. by Actavis, two products have Abbreviated
New Drug Applications currently awaiting regulatory approval, and one
product has been approved but is not currently marketed pursuant to a
settlement agreement. The closings of the purchase agreements are
contingent upon the consummation of Actavis' acquisition of Warner
Chilcott plc.
The product currently marketed is Zenchent Fe™ (norethindrone
acetate/ethinyl estradiol), the generic version of Femcon Fe™. Amneal
expects
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in